GlobeImmune (GBIM) Very Bullish Session; Athersys (ATHX) Upward Earnings-Reaction


The price of GlobeImmune Inc. (Nasdaq:GBIM) stock soared more than 134% to touch the $2.67 mark in intraday trading Friday, finally closing at $2.38, up $1.24 (or +108.77%), with a total volume of 4,974,627 shares traded during the day, representing a huge increase in activity versus its average volume (3m) of 40,997. However, there appears to be no recent news from or even about the company in the street that may explain the stock’s rally.

GlobeImmune, which focuses on developing therapeutic products for cancer and infectious diseases based on its proprietary Tarmogen platform, has 5.75M Shares Outstanding, Market Capitalization (intraday) of $13.69M and GBIM stock 52-week range is between $0.72 and $10.95 per share



Brokerage firm Maxim Group reiterated a Buy rating on Athersys, Inc. (Nasdaq:ATHX) stock and raised its price target from $5.00 to $10.00 after the company delivered strong financial performance in its quarterly financial results

For the fourth quarter 2015, Athersys posted revenues of $10.6 million – including a $10 million license fee from Chugai – compared to $0.2 million in the same period the prior year, and net income of $3.6 million (also including the Chugai license fee), or $0.04 per diluted share, versus a net loss of ($6.6) million, or ($0.08) per diluted share in the same quarter a year ago.

ATHX stock closed at $2.18, up $0.35 (or +19.13%), and 6,436,726 of its shares exchanged hands on Friday’s trading session

Athersys, an international biotechnology company, has 83.33M Shares Outstanding, Market Capitalization (intraday) of $181.66M and ATHX stock one-year range is from $0.90 to $3.43 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at